Literature DB >> 8724532

Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia.

J E Reittie1, K L Yong, P Panayiotidis, A V Hoffbrand.   

Abstract

There is now good evidence that tumour necrosis factor [TNF] stimulates DNA synthesis of B-chronic lymphocytic leukaemia (B-CLL) cells. The malignant clone produces TNF, and addition of exogenous TNF up-regulates the TNF mRNA in B-CLL cells. Interleukin-6 (rIL-6) may also be important in this growth loop. We studied the interaction of TNF and IL-6 in the regulation of DNA synthesis (3H-TdR uptake), cytokine release and cell survival in CLL cells in vitro. Addition of TNF (100 U/ml over 5 days) enhanced DNA synthesis from 718 +/- 284 (mean cpm +/- SE) to 2730 +/- 545 compared to cells cultured in medium alone (n = 16, p < 0.01). TNF-alpha induced DNA synthesis was inhibited in all cases studied by the addition of anti-TNF monoclonal antibody (5 micrograms/ml) to cell cultures. Spontaneous IL-6 protein release was enhanced in the presence of TNF (100 U/ml and 250 U/ml) by CLL cells at 48 hours of culture 143.6% and 172% (p < 0.05, n = 6). At 120 hours of culture, the increase was 323% and 412.5% (4 of 7 cases) of the control respectively. IL-6 (100 U/ml or greater) increased spontaneous DNA synthesis (3H-TdR uptake) but, in the presence of high concentrations of TNF-alpha, inhibited TNF induced DNA synthesis in a dose dependent manner. Cell survival was reduced in the presence of anti-IL-6 mAb, while IL-6 was able to protect CLL cells from spontaneous apoptosis. These results suggest that IL-6 in an autocrine manner may inhibit DNA synthesis but prolongs survival in CLL cells. Increased serum IL-6 levels were detected in 27 of 50 cases of CLL, the mean level being significantly higher in Rai Stage III and IV cases compared to Rai Stage O-II cases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8724532     DOI: 10.3109/10428199609051732

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

Review 2.  New treatments for chronic lymphocytic leukemia.

Authors:  Asher A Chanan-Khan
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

3.  Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

Authors:  Asher A Chanan-Khan; Kasyapa Chitta; Noreen Ersing; Aneel Paulus; Aisha Masood; Taimur Sher; Abhisek Swaika; Paul K Wallace; Terry L Mashtare; Greg Wilding; Kelvin Lee; Myron S Czuczman; Ivan Borrello; Naveen Bangia
Journal:  Br J Haematol       Date:  2011-10-20       Impact factor: 6.998

4.  Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Authors:  Sarah E M Herman; Amber L Gordon; Amy J Wagner; Nyla A Heerema; Weiqiang Zhao; Joseph M Flynn; Jeffrey Jones; Leslie Andritsos; Kamal D Puri; Brian J Lannutti; Neill A Giese; Xiaoli Zhang; Lai Wei; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

5.  Cytokine expression in B-CLL in relation to disease progression and in vitro activation.

Authors:  M Aguilar-Santelises; D Gigliotti; L M Osorio; A D Santiago; H Mellstedt; M Jondal
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

6.  CD84 mediates CLL-microenvironment interactions.

Authors:  A Marom; A F Barak; M P Kramer; H Lewinsky; I Binsky-Ehrenreich; S Cohen; A Tsitsou-Kampeli; V Kalchenko; Y Kuznetsov; V Mirkin; N Dezorella; M Shapiro; P L Schwartzberg; Y Cohen; L Shvidel; M Haran; S Becker-Herman; Y Herishanu; I Shachar
Journal:  Oncogene       Date:  2016-07-25       Impact factor: 9.867

7.  BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia.

Authors:  Yo-Ting Tsai; Aparna Lakshmanan; Amy Lehman; Bonnie K Harrington; Fabienne McClanahan Lucas; Minh Tran; Ellen J Sass; Meixiao Long; Alan D Flechtner; Florinda Jaynes; Krista La Perle; Vincenzo Coppola; Gerard Lozanski; Natarajan Muthusamy; John C Byrd; Michael R Grever; David M Lucas
Journal:  Blood Adv       Date:  2017-10-30

Review 8.  Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

Authors:  Yair Herishanu; Ben-Zion Katz; Andrew Lipsky; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2013-04       Impact factor: 3.722

9.  Regulatory B cells and allergic diseases.

Authors:  Geunwoong Noh; Jae Ho Lee
Journal:  Allergy Asthma Immunol Res       Date:  2011-05-30       Impact factor: 5.764

Review 10.  Involvement of memory T-cells in the pathophysiology of chronic lymphocytic leukemia.

Authors:  Rodolfo Patussi Correia; Flávia Amoroso Matos E Silva; Nydia Strachman Bacal; Paulo Vidal Campregher; Nelson Hamerschlak; Gustavo P Amarante-Mendes
Journal:  Rev Bras Hematol Hemoter       Date:  2014
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.